Chris Degnan, CFO of UroGen Pharma Ltd. ($URGN), made one open market sale of common shares in the last 365 days, totaling $37,121, with the most recent on October 8, 2025. This ranks his sales volume 10,667th among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. He had no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2026 | UroGen Pharma Ltd. | $URGN | Degnan Chris | Chief Financial Officer | A | Restricted Stock Units | 32609 | $0.00 | 32,609.0000 | 48,057,386 | 9999.99% | 0.07% |
| Oct. 8, 2025 | UroGen Pharma Ltd. | $URGN | Degnan Chris | Chief Financial Officer | M | Ordinary Shares | 4483 | $0.00 | 4,483.0000 | 48,057,386 | 9999.99% | 0.01% |
| Oct. 8, 2025 | UroGen Pharma Ltd. | $URGN | Degnan Chris | Chief Financial Officer | S | Ordinary Shares | 2203 | $16.85 | 2,280.0000 | 48,057,386 | 49.14% | 0.00% |
| Oct. 8, 2025 | UroGen Pharma Ltd. | $URGN | Degnan Chris | Chief Financial Officer | M | Restricted Stock Units | 4483 | $0.00 | 8,967.0000 | 48,057,386 | 33.33% | 0.01% |
| Oct. 8, 2024 | UroGen Pharma Ltd. | $URGN | Degnan Chris | Chief Financial Officer | A | Restricted Stock Units | 13450 | $0.00 | 13,450.0000 | 46,779,637 | 9999.99% | 0.03% |
| Oct. 8, 2024 | UroGen Pharma Ltd. | $URGN | Degnan Chris | Chief Financial Officer | A | Employee Stock Option (right to buy) | 74142 | $0.00 | 74,142.0000 | 46,779,637 | 9999.99% | 0.16% |
| March 13, 2023 | Galera Therapeutics, Inc. | $GRTX | Degnan Chris | Chief Financial Officer | P | Common Stock | 10000 | $1.96 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 25, 2023 | Galera Therapeutics, Inc. | $GRTX | Degnan Chris | Chief Financial Officer | A | Stock Option (Right to Buy) | 185000 | $0.00 | 185,000.0000 | 0 | 9999.99% | 0.00% |